Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
42% Complete Response At Six Months Matches Auto-CAR-Ts
Executive Summary
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.
You may also be interested in...
India's ImmunoACT Gears To Deliver CAR-T Therapy At Close To Transplant-Like Prices
ImmunoACT gets go-ahead in India for its CD19-targeted CAR-T cell therapy, which reported low toxicity and the absence of neurotoxicities in clinical trials. The product will come at a huge price differential compared to on-market therapies, offering new hope to several patients.
Allo CAR-T Is Still On The Shelf As Precision Moves On
Precision Biosciences is exiting the allogeneic CAR-T field after four years in early clinical trials, selling off its former lead asset for just $21m.
Caribou’s Phase I CAR-T Data In Lymphoma Show Improvement In Durability
CB-010 still has a way to go, but data from 16 patients in the ANTLER trial showed a higher six-month CR rate than when the company reported data for five patients at EHA in 2022.